Drug
Aln Ttr01
Aln Ttr01: highest development phase Phase 1, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-TTR01 NCT01148953 | Phase 1 | Transthyretin Mediated Amyloidosis (ATTR) |
Latest
No recent events.
Follow Aln Ttr01 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.